Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 4/20 | 0.32 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10527357 | 0.86 | CYP3A4 (0.45) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL11684804 | 0.83 | TRPA1 (0.42) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL11686772 | 0.83 | TRPA1 (0.42) | CYP3A4TRPA1TDP1MAPK1ALDH1A1 | |
| SCHEMBL11681643 | 0.83 | TRPA1 (0.42) | CYP3A4TRPA1TDP1MAPK1ALDH1A1 | |
| SCHEMBL10918491 | 0.82 | TDP1 (0.41) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL17130393 | 0.82 | EPHX2 (0.46) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL1555311 | 0.81 | MAPK1 (0.56) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL3977319 | 0.81 | MAPK1 (0.40) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL2651707 | 0.80 | CYP3A4 (0.38) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL29873844 | 0.78 | SLC22A12 (0.38) | CYP3A4TRPA1TDP1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145913-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-115215807-A | Inhibition of OLIG2 activity | 科泰纳制药公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| EP-3504195-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2018039621-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018039621-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-0153127-B1 | N-ARYL-3-ARYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDES, PROCESSES FOR THEIR PRODUCTION, INSECTICIDAL COMPOSITIONS CONTAINING THEM AND METHODS FOR COMBATTING INSECTS | ROHM AND HAAS COMPANY (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4863947-A | PESTICIDES, INSECTICIDES | ROHM AND HAAS (US) | 1989-09-05 | — | — | US | disclosed |
| US-4663341-A | Insecticidal n-aryl-3-aryl-4,5-dihydro-1h-pyrazole-1-carboxamides | ROHM AND HAAS COMPANY (US) | 1987-05-05 | — | — | US | disclosed |
| EP-0153127-A2 | N-aryl-3-aryl-4,5-dihydro-1H-pyrazole-1-carboxamides, processes for their production, insecticidal compositions containing them and methods for combatting insects | ROHM AND HAAS COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | CYP3A4 4877/4885TRPA1 4344/4885TDP1 3233/4885 |
| US-12145913-B2 | Inhibition of Olig2 activity | POU2F2, POU2F1, PLP2 | CYP3A4 4823/4885TRPA1 3535/4885TDP1 3188/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | CYP3A4 4859/4885TRPA1 4227/4885TDP1 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.